I-Mycobacterium Tuberculosis Nucleic Acid kunye neRifampicin(RIF),Resistance(INH)
Igama lemveliso
I-HWTS-RT147 Mycobacterium Tuberculosis Nucleic Acid kunye neRifampicin(RIF), (INH) Detection Kit (Melting Curve)
I-Epidemiology
I-Mycobacterium tuberculosis, egama linguTubercle bacillus (TB), yintsholongwane ebangela isifo sephepha, kwaye okwangoku, amayeza okuqala okulwa nesifo sephepha asetyenziswa rhoqo aquka i-isoniazid, i-rifampicin kunye ne-ethambutol, njl.[1]Nangona kunjalo, ngenxa yokusetyenziswa gwenxa kwamayeza okulwa nesifo sephepha kunye neempawu zesakhiwo sodonga lweseli se-mycobacterium tuberculosis ngokwayo, isifo sephepha se-mycobacterium siye safumana ukuxhathisa amayeza okulwa nesifo sephepha, kwaye uhlobo oluyingozi kakhulu yi-multidrug-resistant tuberculosis (MDR-TB), exhathisa amayeza amabini aqhelekileyo nasebenzayo, i-rifampicin kunye ne-isoniazid.[2].
Ingxaki yokunganyamezelani namayeza esifo sephepha ikho kuwo onke amazwe apho kuphandwe khona yi-WHO. Ukuze kubonelelwe ngezicwangciso zonyango ezichanekileyo ngakumbi kwizigulane zesifo sephepha, kuyimfuneko ukufumanisa ukunganyamezelani namayeza okulwa nesifo sephepha, ingakumbi ukuxhathisa kwe-rifampicin, okuye kwaba linyathelo lokuxilonga elicetyiswa yi-WHO kunyango lwesifo sephepha.[3]Nangona ukufunyanwa kokuxhathisa kwe-rifampicin kufana kakhulu nokufunyanwa kwe-MDR-TB, ukufumanisa kuphela ukuxhathisa kwe-rifampicin kuyabatyeshela abaguli abane-INH enganyangekiyo (ebhekisa ekuxhathiseni kwi-isoniazid kodwa enovelwano kwi-rifampicin) kunye ne-rifampicin enganyangekiyo (uvelwano kwi-isoniazid kodwa enovelwano kwi-rifampicin), nto leyo enokubangela ukuba abaguli banikwe unyango lokuqala olungenangqiqo. Ke ngoko, uvavanyo lokuxhathisa i-isoniazid kunye ne-rifampicin zezona mfuno zibalulekileyo kuzo zonke iinkqubo zolawulo lwe-DR-TB.[4].
Iiparameters zobugcisa
| Indawo yokugcina izinto | ≤-18℃ |
| Beka ubomi kwishelufa | Iinyanga ezili-12 |
| Uhlobo lweSibonelelo | Isampuli yesikhohlela, Inkcubeko Eqinileyo (LJ Medium), Inkcubeko Yolwelo (MGIT Medium) |
| CV | <5.0% |
| I-LoD | I-LoD yekhithi yokufumanisa isifo sephepha seMycobacterium yi-10 bacteria/mL;I-LoD yekhithi yokufumanisa uhlobo lwe-rifampicin lwasendle kunye nohlobo lwe-mutant yi-150 bacteria/mL; I-LoD yekhithi yokufumanisa uhlobo lwasendle lwe-isoniazid kunye nohlobo lwe-mutant yi-200 bacteria/mL. |
| Ukuchaneka | 1) Akukho mpendulo ihambelanayo xa usebenzisa ikhithi ukufumanisa i-DNA ye-genomic yomntu (500ng), ezinye iintlobo ezingama-28 zezifo zokuphefumla, kunye neentlobo ezingama-29 ze-mycobacteria ezingezizo iintsholongwane (njengoko kubonisiwe kwiTheyibhile 3).2) Akukho mpendulo ihambelanayo xa usebenzisa ikhithi ukufumanisa iindawo zotshintsho kwezinye iijini ze-rifampicin kunye ne-isoniazid sensitive Mycobacterium tuberculosis (njengoko kubonisiwe kwiTheyibhile 4).3) Izinto eziphazamisayo eziqhelekileyo kwiisampulu eziza kuvavanywa, ezifana ne-rifampicin (9mg/L), i-isoniazid (12mg/L), i-ethambutol (8mg/L), i-amoxicillin (11mg/L), i-oxymetazoline (1mg/L), i-mupirocin (20mg/L), i-pyrazinamide (45mg/L), i-zanamivir (0.5mg/L), amayeza e-dexamethasone (20mg/L), azinampembelelo kwiziphumo zovavanyo lwekhithi. |
| Izixhobo Ezisebenzayo | Iinkqubo ze-PCR ze-SLAN-96P zeXesha langempela (iHongshi Medical Technology Co., Ltd.), Inkqubo ye-PCR ye-BioRad CFX96 yeXesha langempela |
Isisombululo se-PCR iyonke







